TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06397911: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Sponsor: Oneness Biotech Co., Ltd. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 114 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$4,076,400

Rescue Site Savings

+$2,683,200

Unlock Full NCT06397911 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06397911 Rescue Dossier →